Investors
and Media

News Releases

Portola Pharmaceuticals to Webcast Presentation at Cowen and Company’s 39th Annual Health Care Conference

SOUTH SAN FRANCISCO, Calif., March 06, 2019 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc.® (Nasdaq: PTLA) today announced that Scott Garland, Portola’s president and chief executive officer, will present a corporate overview at Cowen and Company’s 39th Annual Health Care Conference in Boston on Tuesday, March 12, 2019 at 8:40 a.m. ET (5:40 a.m. PT).

Webcast Details
To access the live investor webcast on Tuesday, March 12, at 8:40 a.m. ET (5:40 a.m. PT), go to the investor section of the company’s website at http://investors.portola.com. A replay will be available for 30 days.

About Portola Pharmaceuticals, Inc.
Portola Pharmaceuticals is a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics that could significantly advance the fields of thrombosis and other hematologic diseases. The Company’s two FDA-approved medicines are Andexxa® [coagulation factor Xa (recombinant), inactivated-zhzo], the first and only antidote for patients treated with rivaroxaban or apixaban when reversal of anticoagulation is needed due to life-threatening or uncontrolled bleeding, and Bevyxxa® (betrixaban), the first and only oral, once-daily Factor Xa inhibitor for the prevention of VTE in adult patients hospitalized for an acute medical illness. The company also is advancing cerdulatinib, a Syk/JAK inhibitor for the treatment of hematologic cancers.

Investor Contact: Media Contact:
Cara Miller Pure Communications
Portola Pharmaceuticals  Portola_Media@purecommunications.com 
ir@portola.com   

Portola Pharmaceuticals Logo

Portola Pharmaceuticals, Inc.